IRVINE, Calif., June 21, 2005 (PRIMEZONE) -- "The focus and importance of new drug development among public companies appears to be at an all-time high," stated SmallCap Sentinel analyst, D.R. Clark. "Driven by expiring patents, aging baby boomers and an always competitive marketplace, companies are endeavoring to harness new science and traverse the regulatory process necessary in bringing new drugs to market. It's at a fever pitch right now."
New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research and development with Western management, joins Vertex Pharmaceuticals Incorporated, Millennium Pharmaceuticals, Inc., and Gilead Sciences, Inc. as companies actively pursuing new drug development.
An informational report regarding New Life Scientific has been made available to the public free of charge via financial courier StockUpTicks.com at:
http://www.stockupticks.com/news_images/NWLF1.pdf
Individuals may also register free of charge for future reports at the following link:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice or research. MP has been paid been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.